This could be interesting, although: 1. I am not sure what is so difficult or time consuming about the current modalities. Ribotyping and toxinotyping are fast enough. But more importantly: 2. I am not sure there would be any clinical utility associated with quick identification of strains, if the patient has CDAD they have CDAD regardless of the ribotype and it's treated in the same way. So what benefit is there, exactly, in identifying the strain rapidly, other than scientific interest? In other words, what clinically actionable information would this give you?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.